Company / EPS (Diluted)
NovoCure Ltd EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.95
FY2025
5-year range
-$1.95 / $0.18
FY2021-FY2025
Trend
-121.6%
vs FY2024
Sector context
#133 of 159
Health Care
What the data says
NovoCure Ltd's eps (diluted) of $-1.95 is lower than 84% of companies in the Health Care sector (FY2025). EPS (Diluted) has declined for 3 consecutive years, from $0.18 in FY2022 to $-1.95 in FY2025.
Based on SEC 10-K filings.
-1.95 in FY2025.
Declined from $-0.56 to $-1.95 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 159This company -$1.95 Sector average $1.66
▼
-217.8% below sector average
Key checks
Key Insights
- NovoCure Ltd's eps (diluted) has declined for 3 consecutive years.
- In FY2025, eps (diluted) decreased 121.6% year-over-year.
- Ranks #133 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.95 | -121.6% |
| FY2024 | -$0.88 | -57.1% |
| FY2023 | -$0.56 | -411.1% |
| FY2022 | $0.18 | +357.1% |
| FY2021 | -$0.07 | +89.9% |
| FY2020 | -$0.69 | -430.8% |
| FY2019 | -$0.13 | +91.6% |
| FY2018 | -$1.54 | +58.0% |
| FY2017 | -$3.67 | +43.2% |
| FY2016 | -$6.46 | +4.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026